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Introduction: This study tested the hypothesis that Major Histocompatibility Complex (MHC) incompatible equine
mesenchymal stromal cells (MSCs) would induce cytotoxic antibodies to donor MHC antigens in recipient horses
after intradermal injection. No studies to date have explored recipient antibody responses to allogeneic donor MSC
transplantation in the horse. This information is critical because the horse is a valuable species for assessing the
safety and efficacy of MSC treatment prior to human clinical application.
Methods: Six MHC heterozygote horses were identified as non-ELA-A2 haplotype by microsatellite typing and used as
allogeneic MHC-mismatched MSC recipients. MHC homozygote horses of known ELA-A2 haplotype were used as MSC
and peripheral blood leukocyte (PBL) donors. One MHC homozygote horse of the ELA-A2 haplotype was the recipient of
ELA-A2 donor MSCs as an MHC-matched control. Donor MSCs, which were previously isolated and immunophenotyped,
were thawed and culture expanded to achieve between 30x106 and 50x106 cells for intradermal injection into the
recipient’s neck. Recipient serum was collected and tested for the presence of anti-donor antibodies prior to MSC injection
and every 7 days after MSC injection for the duration of the 8-week study using the standard two-stage lymphocyte
microcytotoxicity dye-exclusion test. In addition to anti-ELA-A2 antibodies, recipient serum was examined for the presence
of cross-reactive antibodies including anti-ELA-A3 and anti-RBC antibodies.
Results: All MHC-mismatched recipient horses produced anti-ELA-A2 antibodies following injection of ELA-A2 MSCs
and developed a wheal at the injection site that persisted for the duration of the experiment. Anti-ELA-A2 antibody
responses were varied both in terms of strength and timing. Four recipient horses had high-titered anti-ELA-A2
antibody responses resulting in greater than 80% donor PBL death in the microcytotoxicity assays and one of these
horses also developed antibodies that cross-reacted when tested on lymphocyte targets from a horse with an
unrelated MHC type.
Conclusions: Allogeneic MSCs are capable of eliciting antibody responses in vivo that can be strong and also
cross-reactive with MHC types other than that of the donor. Such responses could limit the effectiveness of
repeated allogeneic MSC use in a single horse, and could also result in untoward inflammatory responses in
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The use of autologous mesenchymal stromal/stem cells
(MSCs) for the treatment of acute injuries is hindered by
the time required to isolate and expand the cells in cul-
ture. The genetic background and age of the patient can
also affect the quantity and quality of MSCs able to be
cultured, making autologous MSC use impossible for
some patients regardless of timing issues [1-4]. Banked
allogeneic MSCs would be highly advantageous for use
in such cases where treatment is indicated at the time of
diagnosis or in which it is not feasible to culture quality
MSCs from the patient. Controversy exists regarding the
immunogenicity of MSCs in vivo, despite considerable
evidence for their nonimmunogenic and immunosup-
pressive properties in vitro [5-13].
The horse is a valuable species for assessing the safety
and efficacy of MSC treatment. Autologous bone marrow-
derived MSCs are used routinely in regenerative therapies
for equine patients to treat musculoskeletal disorders in-
cluding tendonitis, osteoarthritis, cartilage damage, and
meniscal injuries [14-20]. In addition, the horse allows for
noninvasive access to large quantities of samples such as
bone marrow aspirate, blood, and serum needed to culture
and test the immunogenicity of allogeneic MSCs. It has
been shown that equine MSCs are uniformly positive for
major histocompatibility complex (MHC) class I expres-
sion but are heterogeneous for MHC class II expression
[21-24]. MSC MHC class II status is also dynamic in the
horse and can vary according to bone marrow aspirate,
MSC passage number, and exposure to interferon gamma
[24]. When the immunogenicity of MHC-matched or mis-
matched MSCs obtained from MHC homozygous
horses was assessed in vitro using modified one-way
mixed leukocyte reactions, it was found that MHC class
II-positive MSCs caused significantly increased re-
sponder T-cell proliferation equivalent to that of the
positive control of MHC mismatched peripheral blood
leukocytes (PBLs) [24]. As the in vitro mixed leukocyte
reaction system is used to examine T-cell responses
only, no conclusion could be made from this study as to
the effect of MHC class I or class II status on the ability
of MSCs to elicit a recipient immune response in vivo,
particularly in terms of antibody production.
Previous studies in swine, rhesus macaques, and mice
have shown that, in contrast to their behavior in vitro,
allogeneic MSCs do elicit cellular and humoral immune
responses when implanted in immunocompetent or
moderately immunosuppressed animals [25-29]. No
studies to date, however, have examined the humoral
(antibody) response to allogeneic MSCs in the horse.
The purpose of this study, therefore, was to evaluate the
immunogenicity of equine MHC-mismatched MSCs
in vivo using lymphocyte microcytotoxicity assays to
measure recipient antibody responses. Our hypothesiswas that MHC-mismatched MSCs would elicit recipient
antibody responses and that these responses would be
independent of MSC MHC class II expression.
Methods
A schematic of the study design and methods is shown in
Figure 1. The Institutional Animal Care and Use Commit-
tee of Cornell University approved the use of horses in
these studies.
Donor horse selection
Thoroughbred horses of known MHC haplotype belong-
ing to the Equine Genetics Center at the Baker Institute
for Animal Health of Cornell University (Ithaca, New
York, USA) were used as MSC and leukocyte donors in
these studies. All donor horses were MHC homozygotes
of equine leukocyte antigen (ELA) haplotype ELA-A2 as
determined previously by ELA serotyping, direct MHC
gene sequencing, and microsatellite typing [30-33]. Bone
marrow aspirates were collected from these horses and
MSCs were isolated and characterized as described previ-
ously for use in in vitro studies [24]. Specifically, MSCs
were immunophenotyped at each passage for expression
levels of MHC class I, MHC class II, and a panel of positive
(CD44, CD29, CD90) and negative (CD11a/CD18,
CD45RB) markers using flow cytometry. Multipotency of
the MSCs was also confirmed via trilineage differentiation
assays [24]. For consistency, all homozygote horses used in
this study (donors and MHC-matched (control) recipient)
were identified and referred to by number as established
previously (Table 1) [24].
MHC-mismatched recipient horse selection and
pre-injection screening
Six healthy adult horses were used as allogeneic MHC-
mismatched MSC recipients in these studies and identi-
fied by letters (Horses A to F) (Table 1). These MHC
heterozygote horses were identified to be of the non-
ELA-A2 haplotype by microsatellite typing using DNA
from horses of known serological and microsatellite
ELA haplotypes as references (Table 2) [32,34]. All re-
cipient horses were screened and found to be negative
for the presence of preexisting anti-ELA-A2 antibodies
prior to their use in this study using microcytotoxicity
assays as described below.
MHC-matched (control) recipient horse selection and
pre-injection screening
As a MHC-matched control, one Thoroughbred MHC
homozygote horse of the ELA-A2 haplotype (Horse 2) be-
longing to the Equine Genetics Center at the Baker Insti-
tute for Animal Health of Cornell University was the
recipient of MSCs from a different ELA-A2 donor. This
horse was also screened and found to be negative for the
Figure 1 Basic schematic of the study design and methods used. ELA-A2, equine leukocyte antigen haplotype; MSC, mesenchymal stromal/stem
cell; PBL, peripheral blood leukocyte.
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use in this study.
Preparation and intradermal injection of donor MSCs
Passage 2 MSCs isolated previously from horses of ELA
haplotype ELA-A2 and identified as either MHC class
II-negative or class II-positive were thawed from liquid
nitrogen storage and expanded by in vitro culture as de-
scribed previously until 30 × 106 to 50 × 106 cells were
attained (Table 1) [24]. This number of cells was chosen
based on a clinically relevant range as well as previous
studies in the literature from other species in which the
stem cell dose was calculated according to body weight
[25-27]. MSCs were lifted from tissue culture plates
using Accumax cell dissociation solution (Innovative
Cell Technologies Inc., San Diego, CA, USA), washed
three times with phosphate-buffered saline to removeTable 1 Recipient horse and donor MSC information
Recipient information Donor (ELA
Horsea Breed Age (years) Sex Horsea M
A Grade 20 Gelding 4 (1) P
B Thoroughbred 15 Gelding 9 P
C Holsteiner 13 Gelding ND P
D Standardbred 16 Gelding 9 P
E Thoroughbred 15 Mare 6 P
F Thoroughbred 18 Gelding 4 (2) P
Control (Horse 2) Thoroughbred 14 Gelding 9 P
ELA-A2, equine leukocyte antigen haplotype; MHC, major histocompatibility complex;
MSC recipients were identified by letter. All MHC homozygote horses were identified b
control recipient. MSCs from all donor ELA-A2 homozygotes were immunophenotyped
was not included in the previous study. Horse ND’s MSCs were positive for MHC class I
described MSCs.residual fetal bovine serum (FBS), counted, and resus-
pended in 1 ml phosphate-buffered saline for injection.
MSCs were maintained at room/ambient temperature
during transport from the laboratory to the recipient
horse [35]. Immediately prior to MSC injection, an ap-
proximately 10 cm × 10 cm area on the left side of the
recipient’s neck was clipped and prepared in a sterile
manner. The MSC suspension was then injected intra-
dermally using a 20 G needle. Recipient horses were
monitored for increased respiratory rate, heart rate, and
body temperature as well as swelling, heat, and pain at
the site of injection for the duration of the study.
Recipient serum sampling
For each recipient, a blood sample was collected pre in-
jection, at the time of injection, and every 48 hours for 4
weeks following injection. After 4 weeks, blood samples-A2) information
SC passage MSC MHC class II status Number of MSCs injected
4 Negative 46 × 106
5 Negative 50 × 106
5 Negative 50 × 106
3 Positive 50 × 106
5 Positive 33 × 106
5 Positive 50 × 106
5 Negative 50 × 106
MSC, mesenchymal stromal/stem cell; ND, not described. aAll MHC-mismatched
y number including the ELA-A2 homozygote that was the MHC-matched MSC
as described previously [24], except for the one donor listed as Horse ND who
and had an expected MSC marker panel consistent with the other previously
Table 2 Microsatellite haplotype data for reference horses and MSC recipient horses
Intra-MHC microsatellite alleles
Class I Class III Class II
Horse Microsatellite haplotype COR110(UMN-JH34-2) TAMU30593 ABGe9019 ABGe9030 TKY3324 COR112 COR113 UM011 COR114
Reference horse
Serological A2/A2 A2 211 343 301 209 269 262 268 174 235
A2 211 343 301 209 269 262 268 174 235
Serological A3/A3 A3a 207 343 311 211 255 254 260 172 243
A3a 207 343 311 211 255 254 260 172 243
Serological A3/A3 A3b 207 343 311 211 255 262 268 176 247
A3c 207 343 311 211 255 262 272 168 255
Serological A5/A5 A5a 221 340 299 212 255 254 260 172 243
A5a 221 340 299 212 255 254 260 172 243
Serological A9/A9 A9a 217 336 307 215 Null 264 272 168 255
A9a 217 336 307 215 Null 264 272 168 255
Serological A10/ A10 A10a 221 342 299 207 255 236 266 179 241
A10b 221 342 311 205 255 236 264 180 243
Recipient horse a
A A5 like 221 340 299 212 255 254 260 172 243
Unknown 223 342 297 219 267 262 264 170 239
B A3 like 207 343 311 211 255 262 260 172 243
A9a like 217 336 307 215 Null 264 272 168 255
C Unknown 211 347 299 212 263 254 260 170 239
A5a like at class II 193 346 318 212 255 254 264 172 243
D A10a like 221 342 299 Failed Failed 236 266 179 241
A10a like 221 340 299 Failed Failed 236 266 179 241
E A3b like 207 343 311 211 255 262 268 176 247
A5a like 221 340 299 212 255 254 260 172 243
F A10a like 221 342 299 207 Failed 236 266 179 241
Unknown 193 346 301 211 Failed 264 270 166 249
Control (Horse 2) A2 211 343 301 209 269 262 268 174 235
A2 211 343 301 209 269 262 268 174 235
ELA-A2, equine leukocyte antigen haplotype; MSC, mesenchymal stromal/stem cell. aThe microsatellite haplotypes assigned to recipient horses in this study were based on knowledge of haplotypes found in other
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collection, approximately 10 ml of blood was collected into
serum blood collection tubes using a Vacutainer needle (BD
Vacutainer, Franklin Lakes, NJ, USA). Serum was allowed to
separate for 8 hours at 4°C and the tubes were then centri-
fuged at 800 × g for 10 minutes at 4°C. Approximately 3 ml
of serum from each time point was aliquoted and frozen
at −20°C for later use in microcytotoxicity assays.
Donor peripheral blood leukocyte isolation
Blood was collected via jugular venipuncture with extension
sets (Baxter Healthcare, Deerfield, IL, USA) and 16 G nee-
dles into 250 ml evacuated containers (Baxter Healthcare)
each containing 3,750 units of heparin (Sigma-Aldrich, St.
Louis, MO, USA). Plasma was allowed to separate for 20
minutes at room temperature and PBLs were then isolated
from the plasma via carbonyl iron (Sigma-Aldrich) granulo-
cyte depletion and Ficoll-Paque Plus (Amersham Biosci-
ences, Piscataway, NJ, USA) gradient centrifugation [24].
This PBL isolation technique consistently results in a range
of lymphocyte purity between 95 and 99% consisting of 80
to 90% T cells and 10 to 20% B cells [24,36]. Isolated PBLs
were resuspended in phosphate-buffered saline and used
fresh for all microcytotoxicity assay experiments at a con-
centration of 30 × 106 cells/ml.
Microcytotoxicity assays to test for the development of
recipient anti-ELA-A2 antibodies
The standard two-stage microcytotoxicity dye-exclusion
test was used to detect recipient antibody responses as
described previously for transplantation studies in the
horse [36,37]. Briefly, fresh PBLs from a donor horse of
the haplotype ELA-A2 were tested against serially diluted
antisera (neat to 1:2,048) from the MSC recipient. One
microliter of diluted antisera and 1 μl donor PBL suspen-
sion were incubated for 30 minutes at room temperature
under oil in wells of Terasaki plates (Robbins Scientific
Corporation, Sunnyvale, CA, USA), following which 5 μl
of rabbit complement (Pel-Freez Biologicals, Rogers, AR,
USA) was added for an additional 1 hour. The wells were
then stained with 2 μl of 5% eosin dye and fixed with 5 μl of
37% formalin (pH between 7.2 and 7.4). The cytotoxic
antibody titer was determined by the highest dilution of each
antisera that resulted in killing of at least 80% of the donor
PBLs [36,37]. All experiments were run in duplicate and
donor cell death was assessed by two authors. For each
experiment, previously established antibody positive or
negative sera were used as internal controls.
Secondary response study for recipient anti-ELA-A2
antibodies
To determine the secondary response to MHC-mismatched
allogeneic MSCs after possible immune priming, any MHC-
mismatched recipient horse with a negative or weak primaryantibody response was to receive a repeat, or second, injec-
tion of donor ELA-A2 MSCs on the right side of the neck
at 5 weeks post initial injection.
Assays to assess the specificity of cytotoxic antibody
responses
To test for antibody specificity against the ELA haplotype,
the serially diluted antisera (neat to 1:2,048) were tested
against fresh PBLs from a donor homozygote horse of the
ELA-A3 haplotype (Horse 5 [24]) using the same time
points as described above through to 4 weeks and the same
methods as described above but with internal control sera
either negative or positive for anti-ELA-A3 antibodies. To
test for recipient formation of anti-red blood cell lysin and
agglutinin antibodies, serum samples from the recipients
were submitted to the Hematology Laboratory at the Uni-
versity of California Davis William R. Pritchard Veterinary
Medical Teaching Hospital (Davis, California, USA). Sam-
ples tested were pre MSC injection, at the peak of anti-ELA-
A2 response, and at the end of the study (8 weeks).
Results
Recipient physical examination findings
All six MHC-mismatched recipient horses developed a
wheal at the injection site that persisted for the duration
of the experiment. For both MHC-mismatched recipient
horses and the control MHC-matched recipient horse,
vital parameters such as respiratory rate, heart rate, and
body temperature remained within normal limits for the
duration of the study.
Microcytotoxicity assay performance
Lymphocyte viability after depletion of granulocytes via
carbonyl iron and isolation using Ficoll-Paque Plus gradi-
ent centrifugation was >95%. Internal control sera known
to be positive for antibodies against the donor PBLs re-
sulted in 80 to 100% donor PBL death and known negative
sera caused no detectable donor PBL death in all assays
performed (Table 3; Additional file 1).
Microcytotoxicity assays to test for the production of
anti-ELA-A2 antibodies by MHC-mismatched recipients
and by the MHC-matched (control) recipient
The sera from all seven recipient horses were tested in the
lymphocyte microcytotoxicity assay against target cells from
a single ELA-A2 homozygous horse (Horse 6 in a previous
study [24]). All MHC-mismatched recipient horses pro-
duced cytotoxic antibodies following intradermal injection
of ELA-A2 MSCs (Figure 2), but the control horse did not
(Table 3). The cytotoxic antibody responses were varied in
strength and timing. Four recipient horses (Horses B, C, E,
and F) had strong antibody responses resulting in >80%
donor PBL death in the microcytotoxicity assays. These four
horses all developed antibodies by 14 days (range 7 to 14
Table 3 Microcytotoxicity assay results for the presence of anti-ELA-A2 antibodies in recipient sera
Recipient serum dilution
Recipient horse Day Neat 1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1,024 1:2,048
A 0 0 0 0 0 0 0 0 0 0 0 0 0
A 7 0 0 0 0 0 0 0 0 0 0 0 0
A 14 0 0 0 0 0 0 0 0 0 0 0 0
A 21 0 0 0 <10 <10 <10 0 0 0 0 0 0
A 28 20 30 35 30 30 15 10 10 10 10 10 10
A 35 0 0 0 0 0 0 0 0 0 0 0 0
A Reinjection = 36 0 0 0 0 0 0 0 0 0 0 0 0
A 42 60 <10 0 0 0 0 0 0 0 0 0 0
A 49 90 <10 0 0 0 0 0 0 0 0 0 0
A 56 50 <10 0 0 0 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0 0 0 0 0 0 0
B 7 0 0 0 0 0 0 0 0 0 0 0 0
B 14 80 80 100 90 10 1 15 0 0 0 0 0
B 21 100 100 100 100 80 25 35 20 10 10 5 0
B 28 45 75 90 80 80 45 15 15 15 25 20 25
B 35 80 90 100 50 0 0 0 0 0 0 0 0
B 42 80 100 25 0 0 0 0 0 0 0 0 0
B 49 80 90 0 0 0 0 0 0 0 0 0 0
B 56 80 30 0 0 0 0 0 0 0 0 0 0
C 0 0 0 0 0 0 0 0 0 0 0 0 0
C 7 45 95 80 15 15 1 0 0 0 0 0 0
C 14 100 100 100 100 100 100 100 100 100 100 80 30
C 21 100 100 100 100 100 100 100 100 100 100 85 50
C 28 100 100 100 100 100 100 100 100 100 55 25 15
C 35 100 100 100 100 100 100 100 100 0 0 0 0
C 42 100 100 100 100 100 100 100 50 0 0 0 0
C 49 100 100 100 100 100 100 100 0 0 0 0 0
C 56 100 100 100 100 100 100 0 0 0 0 0 0
D 0 0 0 0 0 0 0 0 0 0 0 0 0
D 7 0 0 0 0 0 0 0 0 0 0 0 0
D 14 0 0 0 0 0 0 0 0 0 0 0 0
D 21 0 0 10 25 25 10 0 0 0 0 0 0
D 28 10 10 10 10 10 10 10 10 10 10 10 10
D 35 0 0 0 0 0 0 0 0 0 0 0 0
D Reinjection = 36 0 0 0 0 0 0 0 0 0 0 0 0
D 42 0 0 0 0 0 0 0 0 0 0 0 0
D 49 0 0 0 0 0 0 0 0 0 0 0 0
D 56 0 0 0 0 0 0 0 0 0 0 0 0
E 0 0 0 0 0 0 0 0 0 0 0 0 0
E 7 0 0 0 0 0 0 0 0 0 0 0
E 14 65 70 100 50 30 15 15 15 10 10 10 10
E 21 50 60 95 50 15 15 15 15 10 10 10 10
E 28 25 90 35 15 10 10 10 10 10 10 10 10
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Table 3 Microcytotoxicity assay results for the presence of anti-ELA-A2 antibodies in recipient sera (Continued)
E 35 0 80 50 0 0 0 0 0 0 0 0 0
E 42 25 25 0 0 0 0 0 0 0 0 0 0
E 49 25 0 0 0 0 0 0 0 0 0 0 0
E 56 25 0 0 0 0 0 0 0 0 0 0 0
F 0 0 0 0 0 0 0 0 0 0 0 0 0
F 7 0 0 0 0 0 0 0 0 0 0 0 0
F 14 25 25 <10 <10 <10 <10 10 15 20 20 20 20
F 21 90 95 95 100 100 90 65 50 25 15 20 10
F 28 40 65 95 90 80 25 20 20 15 10 15 15
F 35 40 80 90 0 0 0 0 0 0 0 0 0
F 42 24 80 25 0 0 0 0 0 0 0 0 0
F 49 40 90 10 0 0 0 0 0 0 0 0 0
F 56 20 80 25 0 0 0 0 0 0 0 0 0
Control (Horse 2) 0 0 0 0 0 0 0 0 0 0 0 0 0
Control (Horse 2) 7 0 0 0 0 0 0 0 0 0 0 0 0
Control (Horse 2) 14 0 0 0 0 0 0 0 0 0 0 0 0
Control (Horse 2) 21 0 0 0 0 0 0 0 0 0 0 0 0
Control (Horse 2) 28 0 0 0 0 0 0 0 0 0 0 0 0
Control (Horse 2) 35 0 0 0 0 0 0 0 0 0 0 0 0
Control (Horse 2) 42 0 0 0 0 0 0 0 0 0 0 0 0
Control (Horse 2) 49 0 0 0 0 0 0 0 0 0 0 0 0
Control (Horse 2) 56 0 0 0 0 0 0 0 0 0 0 0 0
Internal control (A2 – sera) Days 0 to 28 0 0 0 0 0 0 0 0 0 0 0 0
Internal control (A2 – sera) Days 35 to 56 0 0 0 0 0 0 0 0 0 0 0 0
Internal control (A2 + sera) Days 0 to 28 100 100 100 100 100 100 100 100 100 100 100 100
Internal control (A2 + sera) Days 35 to 56 100 100 100 100 100 100 100 100 100 100 100 100
Data reported as the percentage death of ELA-A2 donor leukocytes. For each time point, the value in italics is the cytotoxic antibody titer (the highest dilution of
each antisera that resulted in killing of at least 80% of the donor leukocytes as reported in Figure 2). ELA-A2, equine leukocyte antigen haplotype.
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1:4 (Horse E) to 1:1,024 (Horse C). In addition, all four of
these horses had circulating antibodies at the conclusion of
the study at 56 days post injection. For Horse C, the cyto-
toxic antibody titer remained high at 1:64 on day 56.
The remaining two MHC-mismatched recipient horses
(Horses A and D) had weak responses resulting in donor
PBL death less than the predefined 80% cutoff used in the
microcytotoxicity assay for reporting titers. Nevertheless,
the antisera from both of these horses resulted in re-
peatable 10 to 35% donor PBL death at dilutions up to
1:32 on day 21 and up to 1:2,048 on day 28 post injec-
tion. The control MHC-matched recipient horse sera
never showed any donor cell killing at any dilution at
any time point (Table 3).
No correlation was found between MHC class II sta-
tus of the donor MSCs and recipient antibody response
in this study. Of the four recipient horses with strong
antibody responses, two received MHC class II-negativeMSCs and two received MHC class II-positive MSCs
(Table 1). Similarly, no correlation was found between
number of donor MSCs injected and the recipient anti-
ELA-A2 antibody response. The lowest number of
donor MSCs used (33 × 106 cells injected into recipient
Horse E) still produced a strong antibody response as
compared with those produced by the two weak re-
sponders (Horses A and D), who received 46 × 106 and
50 × 106 cells, respectively.Secondary response study for the production of
anti-ELA-A2 antibodies by MHC-mismatched recipients
Horses A and D with weak anti-ELA-A2 antibody re-
sponses following initial ELA-A2 MSC injection re-
ceived a second injection of ELA-A2 MSCs at week 5
(day 36) of the study (Figure 2 and Table 3). Following
this second injection, Horse A did go on to develop
anti-ELA-A2 antibodies resulting in >80% donor PBL
Figure 2 Cytotoxic antibody responses to allogeneic (major histocompatibility complex class I and class II mismatched) donor ELA-A2 mesenchymal
stromal/stem cells by recipient horses A to F. The cytotoxic antibody titer was determined by the highest dilution (N) of each recipient serum sample that
resulted in killing of at least 80% of donor peripheral blood leukocytes (PBLs). Ab, antibodies detected by the presence of donor PBL death, but with donor
PBL death below the cutoff value of 80%; No Ab, no antibodies detected (no donor PBL death). As shown, four recipient horses (Horses B, C, E, and F) had
strong anti-ELA-A2 antibody responses which persisted for the duration of the experiment, while two recipient horses (Horses A and D) had weak responses.
∨Both weak responders A and D received a second injection of donor mesenchymal stromal/stem cells at 5 weeks (35 days). ELA-A2, equine leukocyte
antigen haplotype.
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(neat). Horse D, however, did not show any evidence of
an anti-ELA-A2 response following the second MSC
cell injection (Figure 2 and Table 3).
Specificity of cytotoxic antibody responses
Only Horse C, the horse with the strongest anti-ELA-
A2 response (Figure 2 and Table 3), developed anti-
ELA-A3 antibodies post injection resulting in ELA-A3
donor PBL death (Additional file 1). These results indi-
cate that the cytotoxic antibodies produced as a result
of MSC injection were directed against epitopes of the
MHC class I antigens of the ELA-A2 homozygous
donor, because there is no detectable sharing of the
MHC class I antigens themselves between the ELA-A2
and ELA-A3 haplotypes [33]. Cross-reactivity of high-
titered anti-MHC antisera generated in transplantation
responses is well known [38].
Similarly, Horse C was the only recipient to develop
unidentified anti-red blood cell lysin antibodies, which
were present in his serum at the peak of his anti-ELA-
A2 response. Horse D, who had a weak primary anti-
ELA-A2 response and did not show any evidence of an
increased anti-ELA-A2 response following a repeat
ELA-A2 MSC injection, did develop unidentified anti-
red blood cell agglutinin antibodies following the repeat
MSC injection (data not shown).Discussion
The results of this study demonstrate that allogeneic equine
bone marrow-derived MSCs can elicit strong antibody re-
sponses after intradermal injection into MHC-mismatched
recipients. Although the strength of the responses varied
between recipients, all recipients developed antibodies
against lymphocytes of the donor ELA-A2 haplotype. Four
of the recipient horses generated strong responses in which
antibodies were present by 7 to 14 days and persisted for
the duration of the study. Overall, the responses seen in
these horses were very similar to those reported previously
in horses following ectopic trophoblast allotransplantation
[37]. Skin allografting and allogeneic pregnancy in the horse
can also induce cytotoxic antibodies with similar response
profiles [39]. Antibody responses to allogeneic MSC trans-
plantation have been reported previously for other species
[25-27]. These results in the horse add to the growing body
of evidence that MSCs are not immunoprivileged, as origin-
ally believed, and suggest that caution must be exercised
when considering the use of allogeneic MSCs.
It is important to note that although FBS was used in the
MSC culture media in this study, FBS cannot be the target
of the anti-donor antibody responses observed. The micro-
cytotoxicity assays used are extremely specific for antibodies
in the recipient antisera that are targeting and killing donor
PBLs. As the donor PBLs do not express bovine proteins
and are never in contact with FBS during their isolation or
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sponsible for their death. While the use of FBS in MSC cul-
ture media up until the time of injection is certainly a
potential concern for clinical application and should be
avoided in a clinical setting or in future studies examining
donor MSC viability in vivo [40], FBS was useful in this
study to standardize donor MSC culture conditions and
growth. Such standardization would have been impossible
using autologous serum from each donor.
There are several conceivable reasons for the variation
in the strength of the antibody responses observed in
this study. The first is potential differences in recipient
health and immune status. Although all recipient horses
had normal physical examinations and were in fair to
good body condition, it is interesting to note that the
two weak responders (Horses A and D) were the only
two recipient horses recently added to the research herd,
while the four strong responders were existing members
of the university teaching or research herd. It is possible
that the immune systems of the two weak responders
were not as strong as the other recipients due to factors
such as improper nutrition prior to their arrival at the
university and/or stress from having gone through the
auction and associated transport as well as being placed
with new herd members. Such factors could increase en-
dogenous glucocorticoid levels and thereby cause im-
mune suppression [41-43]. As summarized in Table 1,
Horse A received MSCs from the same donor horse
(Horse 4) as Horse F, who had a strong antibody re-
sponse. Similarly, Horse D received MSCs from the
same donor horse (Horse 9) as Horse B, who had a
strong antibody response, suggesting that the recipient
health and immune status is the factor likely to be af-
fecting the antibody response.
There is also the possibility that some of the strong re-
sponders may have had a previous primary response
against the ELA-A2 haplotype. While this seems unlikely
given that the majority of these horses had long-term
known histories and health records with the university,
it is possible that the recipient mare could have been
pregnant in the past or that the geldings could have
been exposed to ELA-A2 antigens through another
mechanism. In particular, recipient Horse C had a re-
sponse that is more typical of a secondary, or primed,
immune response than of a primary immune response.
This horse developed detectable antibodies by 7 days
post injection and had very high titers that remained
high for the duration of the study. While all recipient
horses were screened for the presence of the circulating
anti-ELA A2 antibodies prior to MSC injection, there
was no practical way to screen them for past exposure
prior to the MSC injections performed in this study.
Although the authors are of the opinion that the recip-
ients themselves are the likely cause of the observedvariability in antibody responses, one must also consider
the fact that different MSCs were used. While this was
done intentionally to test for possible differences in re-
sponse to MSC MHC class II expression, this difference
could have affected the results in several ways because
MSCs are not only heterogeneous in their basal MHC
class II expression, but also dynamic in their MHC expres-
sion as has been demonstrated previously with interferon
gamma stimulation [24]. It is possible that the preinjection
expression levels of either MHC class I or MHC class II
could have changed post injection. While no differences
were observed in this study between responses elicited by
MHC class II-positive MSCs compared with MHC class
II-negative MSCs, a relatively small number of horses
were examined and this study primarily evaluated a MHC
class I-driven antibody response. Injection site biopsies to
examine a cellular response were considered but ultim-
ately not performed due to concerns about removing the
MSC antigen source and thereby altering the antibody re-
sponse results.
Lastly, the observed results for the two weak responders
that received repeat MSC injections might be misleading
due to the fact that both horses had circulating anti-ELA-
A2 antibodies at least very close to the time of the repeat
injection. It is possible that the donor MSCs injected in
week 5 may have been targeted by circulating antibodies
and destroyed before they could induce a secondary anti-
body response. This would be a potential explanation for
why Horse D did not develop a further antibody response.
The doses of MSCs used in this study were clinically
relevant and proportionally similar on a body weight
scale (approximately 0.1 million MSCs/kg body weight)
to those originally used in allogeneic MSC studies in
other species [25-27]. Recent publications from human
autologous and allogeneic bone marrow-derived MSC
clinical trials, however, have reported using much higher
doses ranging from 0.3 to 10 million MSCs/kg body
weight, with some evidence that 2 to 5 million MSCs/kg
body weight is optimal for immunomodulation [44]. In
this study a wide range of MSC doses was not examined.
Ultimately, it may not even be feasible to culture enough
equine MSCs to reach the higher doses reported for
humans on a million MSCs/kg body weight basis.
In this study only bone marrow-derived MSCs were ex-
amined and they were delivered via intradermal injection.
In addition, semi-allogeneic recipients were not included.
The effect that more clinically relevant injection site loca-
tions may have on recipient antibody response remains to
be determined, as does the effect of the MHC haplotypes
of the clinical MSC donor and recipient. Clinical patients
are not expected to be MHC homozygotes or completely
matched in terms of their MHC haplotype. Given the fre-
quency distribution of MHC haplotypes in breeds such as
the Thoroughbred or Standardbred, it is possible that
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lected donor MSCs [30-33]. Future studies taking these fac-
tors into account and also comparing bone marrow-derived
MSCs with other MSC types are certainly warranted.
Finally, perhaps the most important finding of this
study in terms of clinical application is the potential for
the development of strong, long-lasting, and possibly
cross-reactive antibody responses after MSC transplant-
ation. Cross-reactivity with diverse MHC class I antigens
happens over time as the immune response progresses
and the recipient develops broader and stronger anti-
bodies against other MHC epitopes that may be shared
against other MHC haplotypes [38]. While a single dose
of allogeneic MSCs might cause no overt harm to the re-
cipient at the time of that injection, there is the possibil-
ity for a more severe systemic reaction following a
second injection or if the patient was ever to receive
other foreign tissues or cells, including a blood transfu-
sion. Also of consideration is the fact that recipients
with strong immune responses or with primed immune
responses may have enough circulating antibodies and
immune effector cells to cause donor MSC death before
they have had the chance to exert their desired regenera-
tive effects. Further research is warranted to determine
whether MHC class I and II expression levels on MSCs
can be manipulated in vitro to an extent that the MSCs
are no longer immunogenic in vivo.
Conclusions
This study is the first to investigate the antibody response
to allogeneic MSC transplantation in the horse. Using
known MHC-mismatched donors and recipients, we have
shown that allogeneic MSCs are indeed capable of elicit-
ing antibody responses in vivo, which can be strong and
also cross-reactive with MHC haplotypes other than the
donor type. These results highlight the potential risk of
clinical allogeneic MSC application.
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